Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
June 05, 2020 01:15 ET
|
Novartis International AG
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving...
Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer
May 18, 2020 07:15 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 11, 2020 16:01 ET
|
Liquidia Technologies, Inc.
Received FDA Acceptance of LIQ861 NDA for ReviewReported Final Safety and Tolerability Results for LIQ861 Inspire TrialManagement to Host Webcast and Conference Call Today at 4:30p.m. ET ...
Novartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma
May 01, 2020 01:15 ET
|
Novartis International AG
CHMP positive opinion advances efforts to provide first-in-class LABA/LAMA/ICS combination for patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment in the EU. Digital...
Circadia Health Commits $3 million in Respiratory Monitors to Global COVID-19 Efforts
April 02, 2020 06:47 ET
|
Circadia Health
LONDON, April 02, 2020 (GLOBE NEWSWIRE) -- Circadia Health announces $3 million in medical devices and services towards COVID-19 relief efforts across the globe. The company has expedited the...
Humidity helps in the fight against COVID-19, virologists report
March 13, 2020 13:32 ET
|
Dan Hess Research
Washington, D.C., March 13, 2020 (GLOBE NEWSWIRE) -- What can the public do to defend against the COVID-19 coronavirus? One simple answer is to ramp up humidification at home and in the workplace,...
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
December 16, 2019 01:15 ET
|
Novartis International AG
Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across treatment...
Immunomodulators Market To Reach USD 239.7 Billion By 2026 | Reports And Data
November 13, 2019 14:55 ET
|
Reports and Data
New York, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Production of advanced drugs, increasing adoption of monoclonal antibodies, and clinical urgency to develop new generation immunomodulators are key...
Cleanspace Launches Halo – a Revolutionary Respirator for the Healthcare Sector
June 10, 2019 07:00 ET
|
CleanSpace Technology
CHICAGO, June 10, 2019 (GLOBE NEWSWIRE) -- CleanSpace Technology, a global manufacturer of next generation respiratory protection equipment, today announced CleanSpace HALO is now available in North...
Earth Science Tech, Inc. Announces Partnership with Bionatus to Help Manufacture, Distribute, & Continue Further R&D on Cannabis (CBD) Products
August 22, 2017 08:25 ET
|
Earth Science Tech, Inc.
Hollywood, FL, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid...